Recent Updates
Recently added Catalysts

SI-BONE, Inc.

SIBNFDA catalysts, PDUFA dates & pipeline intelligence
$23.16
▼ -0.25 · -1.07%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SIBN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $11.4852W HIGH $25.92
Volume
875.92 K
Value Traded
20.27 M
Short % Float
10.55%
Days to Cover
6.8
-7.14%Week
+17.8%1 Month
+16.32%3 Month
+56.28%6 Month
-55.05%5 Year
-30.1%All Time

Cash Data

Unlock SIBN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
1.04 B
EPS (TTM)
-0.30
P/E Ratio
-
Ent. Value
934.22 M
Total Shares
45.11 M
Float Shares
42.90 M
Insiders
4.90%
Institutions
109.47%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every SIBN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SIBN Catalyst Timeline

Dated clinical, regulatory and corporate events for SI-BONE, Inc.

Unlock the full SIBN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SIBN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all SIBN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

SI-BONE, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every SIBN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every SIBN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SIBN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Maheshwari AnshulOfficer (Chief Op & Financial Officer)Sell -3,247 211,250 held$25.00 11/04/2026
Unlock the full SIBN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
PARKMAN HEALTHCARE PARTNERS LLC 0.7 % (40 %) 7.38 M 392.80 K 19.51% ( 64.12 K)
Unlock every fund holding SIBN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SIBN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SIBN ownership
Insider and institutional ownership, quarter by quarter.

SIBN Short Interest

Shares sold short, counted twice a month.

10.55%
Short % of Float
of tradable shares sold short
4.5M
Shares Sold Short
-3.8% vs prior count
6.8 High
Days to Cover
trading days of normal volume to buy every short share back
661.9K
Avg Daily Volume
the average used for days to cover
Unlock SIBN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock SIBN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SIBN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SIBN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SIBN ranks across every disease it competes in

Competitive Position is a premium feature
See how SIBN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SIBN News

SIBN
Nov 2, 2026
SIBNGeneral
▲ +17.6%on this news

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue Guidance

SI-BONE, Inc. reported a 14.5% increase in worldwide revenue for Q3 2026, reaching $55.7 million. The company achieved positive adjusted EBITDA of $3.0 million and reaffirmed its revenue guidance for the year. Despite a net loss of $3.6 million, SI-BONE noted significant growth in procedure volumes and active physicians.

Read more →
SIBN
Oct 29, 2026
SIBNConferences/Events
▼ -5.3%on this newsshared move

SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026

SI-BONE, Inc. (Nasdaq: SIBN) will present at the UBS Global Healthcare Conference in Palm Beach Gardens on November 10, 2026. Management hosts a fireside chat at 2:00 p.m. Pacific Time. Investors can register for the live webcast via the company website. The audio will remain archived for at least 90 days after the event.

Read more →
SIBN
Oct 19, 2026
SIBNConferences/Events

SI-BONE To Report Third Quarter 2026 Financial Results on November 2, 2026

SI-BONE, Inc. will report its financial results for Q3 2026 on November 2, 2026. The company will host a conference call at 1:30 p.m. PT to discuss these results. Investors can register for the call and access a live audio webcast on the company's website. SI-BONE is recognized for its advancements in procedural solutions for compromised bone health.

Read more →
SIBN
Sep 28, 2026
SIBNFDA Updates

SI-BONE Receives FDA 510(k) Clearance for iFuse Granite Onyx™, Extending Its Compromised Bone Franchise Beyond the Pelvis

SI-BONE, Inc. has received FDA 510(k) clearance for its iFuse Granite Onyx System, marking its first product aimed at addressing compromised bone outside the pelvis. This innovative system targets loosening in spinal fusion constructs, particularly for patients with low bone density. The Onyx system aims to enhance osseointegration and reduce revision rates, thereby improving surgical outcomes.

Read more →
SIBN
Aug 31, 2026
SIBNConferences/Events

SI-BONE To Present at Morgan Stanley 24th Global Healthcare Conference on September 14, 2026

SI-BONE, Inc. will participate in the 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York. The company will host a fireside chat on September 14, 2026, at 8:30 a.m. PT. Investors can register to listen live or access the archived webcast on the company's website.

Read more →
SIBN
Aug 3, 2026
SIBNGeneral

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. reported a 15.2% increase in worldwide revenue for Q2 2026, totaling $56 million. The company also improved its adjusted EBITDA by 178% to $2.8 million. Despite a net loss of $4.1 million, the firm raised its 2026 revenue guidance, reflecting confidence in its growth strategy and market demand. The upcoming launch of a breakthrough device and favorable reimbursement changes are expected to further enhance revenue.

Read more →
SIBN
Jul 20, 2026
SIBNConferences/Events

SI-BONE To Report Second Quarter 2026 Financial Results on August 3, 2026

SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2026 on August 3, 2026. The report will be followed by a conference call at 1:30 PM PT. Investors can access the call via registration or through a live webcast on the company's website.

Read more →
SIBN
Jun 4, 2026
SIBNConferences/Events
▲ +6.9%on this news

SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026

SI-BONE, Inc. will participate in the 2026 Truist Securities MedTech Conference in Boston on June 16, 2026. The company will host a fireside chat at 5:40 a.m. PT. Interested investors can register to listen to the conference call, which will also be available for replay on their website for 90 days post-event.

Read more →
SIBN
May 11, 2026
SIBNGeneral
▼ -5.4%on this news· ran to +19% by day 3

SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance

SI-BONE, Inc. reported strong financial results for Q1 2026, with worldwide revenue of $52.6 million, an 11.2% increase from the previous year. The company also improved its adjusted EBITDA significantly and raised its revenue guidance for the year. Despite a net loss of $4.3 million, the overall performance indicates a positive trend in growth and market expansion.

Read more →
SIBN
Apr 30, 2026
SIBNConferences/Events

SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026

SI-BONE, Inc. will participate in the 2026 BofA Securities Healthcare Conference in Las Vegas on May 12, 2026. The company will host a fireside chat to discuss its procedural solutions for compromised bone. Investors can register for the event and access a live audio webcast on the company's website.

Read more →
SIBN
Apr 20, 2026
SIBNConferences/Events

SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026

SI-BONE, Inc. will report its first-quarter 2026 financial results on May 11, 2026, after market close. A conference call will follow at 1:30 p.m. PT, where investors can register to listen. The company has a strong focus on developing solutions for compromised bone and has conducted over 140,000 procedures since its inception.

Read more →
SIBN
Feb 24, 2026
SIBNGeneral

SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance

SI-BONE, Inc. reported strong financial results for Q4 2025, with a 15% increase in worldwide revenue and a positive adjusted EBITDA of $5.1 million. The company achieved a 20% revenue growth for the entire fiscal year and provided optimistic guidance for 2026, expecting revenue between $228.5 million and $232.5 million. Despite improvements, SI-BONE continues to face challenges with operating losses and rising expenses.

Read more →
SIBN
Feb 18, 2026
SIBNConferences/Events

SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026

SI-BONE, Inc. announced its participation in the TD Cowen 46th Annual Health Care Conference scheduled for March 2, 2026. The company will host a fireside chat at 7:30 a.m. PT. Investors can register for the call and access a live audio webcast on the company's website, which will be archived for 90 days.

Read more →
SIBN
Feb 3, 2026
SIBNConferences/Events

SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026

SI-BONE, Inc. will report its financial results for Q4 and the full year of 2025 on February 23, 2026. The announcement includes details about a conference call for investors, which will take place at 1:30 p.m. PT. The company is recognized for its expertise in procedural solutions related to compromised bone.

Read more →
SIBN
Jan 13, 2026
SIBNGeneral

SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025

SI-BONE, Inc. announced preliminary revenue figures for the fourth quarter and full year 2025, estimating worldwide revenue between $200.8 million and $200.9 million, reflecting a growth of about 20%. The company plans to release detailed financial results in late February 2026. However, these figures are preliminary and may undergo significant adjustments pending audit procedures.

Read more →
SIBN
Nov 18, 2025
SIBNConferences/Events

SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025

SI-BONE, Inc. announced its participation in the Piper Sandler 37th Annual Healthcare Conference, scheduled for December 2, 2025. The event will feature a fireside chat with management, providing an opportunity for investors to engage. SI-BONE is recognized for its advancements in treating sacropelvic disorders and has a robust clinical evidence base.

Read more →
SIBN
Nov 10, 2025
SIBNGeneral
▲ +16.2%on this news

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance

SI-BONE, Inc. reported a 21% increase in revenue for Q3 2025, reaching $48.7 million, driven by strong demand for its products. The company also improved its adjusted EBITDA to $2.3 million and raised its 2025 revenue guidance to between $198 million and $200 million. However, operating expenses rose by nearly 12%, impacting profitability.

Read more →
SIBN
Oct 20, 2025
SIBNConferences/Events

SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025

SI-BONE, Inc. will announce its third quarter 2025 financial results on November 10, 2025. The company, known for its innovative solutions for sacropelvic disorders, will host a conference call at 1:30 p.m. PT. Investors can register for the call and access the webcast on the company's website.

Read more →
SIBN
Aug 26, 2025
SIBNConferences/Events

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025

SI-BONE, Inc. will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. The company will host a fireside chat to discuss its innovations in treating sacropelvic disorders. Investors can listen to the live webcast and access an archived version for 90 days post-event. SI-BONE is recognized for its pioneering work in minimally invasive SI joint surgery.

Read more →
SIBN
Aug 4, 2025
SIBNGeneral

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance

SI-BONE, Inc. reported substantial financial growth in the second quarter of 2025, with a 22% increase in U.S. revenue and a cash flow breakeven status. The company achieved positive Adjusted EBITDA of $1.0 million and an improved net loss of $6.2 million. The firm also announced a leadership transition with the planned retirement of President Tony Recupero, highlighting continued innovation and growing engagement among U.S. physicians. SI-BONE raised its full-year 2025 revenue guidance, anticipating worldwide revenue of $195 million to $198 million.

Read more →

About SI-BONE, Inc.

San Jose, CA 376 employees si-bone.com
Headquarters88 W. PLUMERIA DRIVE, SAN JOSE, CA, 95134
BIOPHARMAWATCH ELITE
Trade the next SIBN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime